Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free VINC Stock Alerts

Vincerx Pharma (VINC) Competitors

Vincerx Pharma logo
$0.02 +0.00 (+31.78%)
As of 05/14/2026 03:46 PM Eastern
Compare

VINC vs. PTPI, ARDS, ADTX, LIPO, and CARM

Should you buy Vincerx Pharma stock or one of its competitors? MarketBeat compares Vincerx Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vincerx Pharma include Petros Pharmaceuticals (PTPI), Aridis Pharmaceuticals (ARDS), Aditxt (ADTX), Lipella Pharmaceuticals (LIPO), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Vincerx Pharma has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Petros Pharmaceuticals Neutral

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Petros Pharmaceuticals N/A -78.22%-23.50%

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Petros Pharmaceuticals$5.11M0.04-$8.16M-$10.07N/A

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 5 of the 9 factors compared between the two stocks.

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Vincerx Pharma N/A -248.33%-132.73%

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Vincerx Pharma Neutral

Aridis Pharmaceuticals has a beta of 49.37, suggesting that its stock price is 4,837% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Vincerx Pharma on 6 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Aditxt?

Vincerx Pharma (NASDAQ:VINC) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Vincerx Pharma has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Aditxt has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
AditxtN/AN/A-$41.71M-$11.10 thousandN/A

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -1,217,927.00%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Aditxt -1,217,927.00%-374.60%-92.82%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vincerx Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Aditxt had 5 more articles in the media than Vincerx Pharma. MarketBeat recorded 5 mentions for Aditxt and 0 mentions for Vincerx Pharma. Aditxt's average media sentiment score of 0.17 beat Vincerx Pharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company Overall Sentiment
Vincerx Pharma Neutral
Aditxt Neutral

Summary

Vincerx Pharma beats Aditxt on 7 of the 12 factors compared between the two stocks.

How does Vincerx Pharma compare to Lipella Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Vincerx Pharma has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Lipella Pharmaceuticals Neutral

Lipella Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Lipella Pharmaceuticals$536.36K0.34-$5.02M-$2.42N/A

Vincerx Pharma has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Summary

Lipella Pharmaceuticals beats Vincerx Pharma on 6 of the 10 factors compared between the two stocks.

How does Vincerx Pharma compare to Carisma Therapeutics?

Vincerx Pharma (NASDAQ:VINC) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Carisma Therapeutics Neutral

Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Vincerx Pharma has higher earnings, but lower revenue than Carisma Therapeutics. Vincerx Pharma is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Vincerx Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vincerx Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

Vincerx Pharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Carisma Therapeutics -254.28%N/A -192.17%

Summary

Carisma Therapeutics beats Vincerx Pharma on 9 of the 14 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VINC vs. The Competition

Export
MetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$89K$935.60M$6.34B$12.37B
Dividend YieldN/A4.84%2.80%5.35%
P/E Ratio0.001.4820.6625.63
Price / SalesN/A115.81544.2776.59
Price / CashN/A20.0743.2656.33
Price / Book0.008.119.876.97
Net Income-$40.16M-$3.91M$3.55B$333.62M
7 Day PerformanceN/A9.43%1.67%1.09%
1 Month PerformanceN/A76.62%0.46%3.08%
1 Year PerformanceN/A140.55%39.37%35.68%

Vincerx Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VINC
Vincerx Pharma
N/A$0.02
+31.8%		N/A-65.6%$89KN/AN/A60
PTPI
Petros Pharmaceuticals
N/A$0.01
+11.3%		N/A-95.1%$193K$5.11MN/A20
ARDS
Aridis Pharmaceuticals
N/A$0.00
+1,300.0%		N/A+2,700.0%$149KN/A0.0330
ADTX
Aditxt
1.0925 of 5 stars		$0.13
-5.4%		N/A-100.0%$130KN/AN/A60
LIPO
Lipella Pharmaceuticals
N/A$0.03
flat		N/A-98.3%$123K$536.36KN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel